We identified a subset of genes involved in chromatin remodeling whose mRNA expression changes in differentiating mouse erythroleukemia (MEL) cells. We furthermore tested their mRNA expression patterns in normal and malignant CD34
Introduction
Hematopoietic differentiation is suppressed in leukemia, suggesting certain genes may affect the genetic program of differentiation. In normal hematopoiesis, stem cells have a selfrenewing capacity 1 and they can also differentiate into rapidly dividing progenitors giving rise to highly specialized mature blood cells. 2 However, in hematologic malignancies leukemia-initiating stem cells retain their self-renewal capacity and give rise to only partially differentiated leukemic blasts without any repopulation activity. 3 In 1997, Zhang et al 4 presented us with evidence that there are clear-cut differences in normal and cancer cells in terms of the gene expression. This provides us with an opportunity to study further the causal factors responsible for these differences instead of looking at consequences of this process. Mutations associated with acute leukemia lead to major changes in gene expression pattern by affecting chromatin remodeling mechanisms such as histone acetylation/deacetylation, histone complex alteration and ATPase-dependent nucleosome-remodeling. 5, 6 The chromatin remodeling genes might thus be responsible for the gene expression differences between normal and malignant cells.
Since our strategy of identification of the leukemia-associated regulatory factors was based upon the presumption that these genes are involved in hematopoietic differentiation, we used a model of MEL cell differentiation representing a useful tool for studying gene expression pattern during erythroid dif- ferentiation. [7] [8] [9] [10] [11] By subtractive hybridization we identified 63 differentially expressed genes in differentiating MEL cells and further focused on a subset of molecules involved in chromatin remodeling. Here we describe SMARCA5 (hSNF2H), human homologue of Drosophila imitation switch gene (ISWI), expressed in hematopoietic tissues and down-regulated during in vivo and in vitro erythroid differentiation. This gene, functionally involved in chromatin remodeling, may play a critical role in malignant hematopoiesis since we demonstrate that primitive hematopoietic cells of AML overexpress SMARCA5.
Materials and methods

In vitro erythroid differentiation of MEL cells
Mouse erythroleukemia (MEL) cell line 707/clone B10/1 was obtained as a kind gift from Dr PR Harrisson from Beatson Institute for Cancer Research, Glasgow, UK. The cells were induced to erythroid differentiation by N,NЈ-hexamethylenebis-acetamide (HMBA) 7 in final 5 mM concentration (the density of 5 × 10 4 cells per ml) in Iscove's modification of Dulbecco's medium (Sigma, St Louis, MO, USA) with 10% fetal bovine serum (The School of Veterinary Medicine, Brno, Czech Republic). The cells were incubated at 37°C, 5% CO 2 and a humidified atmosphere for 4 days. At day 4 of culture hemoglobinized MEL cells were cytospinned and o-dianidisine stained for the detection of hemoglobin. HMBA-induced at day 4 and non-induced MEL cells were lyzed in RNazol (Molecular Research Center, Cincinnati, OH, USA) and total RNA was isolated.
Differential display and subtractive hybridization
Delta Differential Display Kit and PCR-Select cDNA Subtraction Kit (both from Clontech, Palo Alto, CA, USA) were used to identify mRNAs that are expressed in one population, but are absent or reduced in another. The templates represented a single stranded oligo (dT)-primed cDNA synthesized from 2 g of mRNA from the induced and non-induced MEL cells isolated with PolyATract mRNA Isolation System IV (Promega, Madison, WI, USA) treated with DNase I (MBI Fermentas, Vilnius, Lithuania). The bands from differential display autoradiographs or subtractive hybridization reactions were re-amplified, subcloned using a TA cloning kit (Invitrogen, Carlsbad, CA, USA), and sequenced on the capillary sequencer ABI 310 (Perkin Elmer, Foster City, CA, USA). All sequences were compared in the databases of National Center for Biotechnology Information (www.ncbi.com).
Leukemia
Northern blotting and semiquantitative RT-PCR
Twenty micrograms of total RNA isolated as above were loaded on 1% agarose formaldehyde-containing gel, blotted on nitrocellulose membrane and hybridized with a 32 P-labeled denatured probe (Amersham, Buckingham, UK) generated by random priming (MBI Fermentas). Blots were analyzed by phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA) and the densitometry data (intensity per area) are included in Figures 1-3 . Semiquantitative RT-PCR was performed on cDNA templates, corresponding to 100 000 cells per sample, generated by reverse transcription (Superscript, Gibco, Life Technologies, Rockville, MD, USA) from DNase I treated total RNA. We observed no genomic DNA contamination in the samples where reverse transcriptase was not added. For leveling of the quantity of cDNA template the cDNA was amplified with ␤-actin (forward: ggtgggcatgggtcagaag, reverse: gctggggtgttgaaggtctc) and glucose-6 phosphate dehydrogenase (G6PD) primers (F: aactcagatgacgtccgtgatg, R: tcacgttcttgtatctgttgcc): 12.5 picomol of each primer for 20, 25, and 30 cycles under optimized conditions in the presence of 1 × PCR buffer, 2 mM MgCl 2 , 0.5 mM of each dNTP and 1 U of Taq DNA polymerase. PCR was performed at the linear phase and templates analyzed for ␤-actin and G6PD revealed approximately the same quantity of cDNA template. Primers corresponding to SMARCA5 (F: aggaccaaaaccttccacacag, R: tcagtaagcagatggacctgatgtc), high mobility group protein-17 (F: catgcccaagagaaaggctg, R: cacttggcatctccagcacc), topoisomerase II (TOP2) (F: caccgctgcagcctgtaaatg, R: taatacaagacatttttgggtccct), high mobility group protein-1 (F: tcaacgacatcttccaggaggt, R: ccagttccagcccttcacac), ␤-globin (F: tggatgaagttggtggtgagg, R: tgcccaggagcctgaagttc), and ␦-aminolevulinic acid synthase-erythroid (ALASE) (F: gaactacaccagaaagactcagc, R: ctacgaaggtcaggctccca) were homologous to human as well as murine sequences (primers were supplied by Generi Biotech, Czech Republic). RT-PCR products were subcloned, sequenced, and further used as the probe tem-
Figure 1
Northern blot analysis of HMG-17, HMG-1, TOP2, and SMARCA5 in HMBA-induced (+) and non-induced (−) MEL cells. HMG-1, TOP2, and SMARCA5 mRNA expression decreases during in vitro differentiation while HMG-17 is up-regulated. Controls were represented by ␤-globin, ALASE, ␤-actin mRNAs, and 18S ribosomal RNA. Densitometry data (intensity per area) are shown on the bottom of each blot.
plates for the Northern blotting and for RT-PCR as positive controls. DNA ladders run in parallel, blank and genomic DNA templates were used as a control.
AML patients and CD34
+ cell isolation 
Murine model of accelerated hematopoiesis induced by phenylhydrazine
Hemolytic anemia was induced in the C3H/HeJ mouse by the intraperitoneal administration of 0.8% phenylhydrazine in saline at the dose of 0.8 mg/10 g mouse b.w. Animals were handled in accordance with the rules of the Institutional Review Board. Hematocrits (hct) were determined for all mice. Erythropoietin (EPO) levels were measured in pooled serum samples using radioimmunoassay (RIA). Polyclonal rabbit antibodies to EPO diluted at 1:20 000 (obtained as a kind gift from Dr Fingerova, Palacky University at Olomouc), 125 I EPO (Amersham), and porcine anti-rabbit antibodies diluted at 1:16 (Swar, Sevac, Czech Republic) were used. The radioactivity of pellets was measured and the concentration of EPO extrapolated on a concurrently determined standard curve.
Results
Chromatin remodeling genes are differentially expressed during erythroid differentiation of MEL cells
MEL cells were analyzed for ␤-globin and ALASE mRNA expression at 0, 24, 48, 72, and 96 h upon HMBA induction. Their expression levels gradually increased and reached the maximum at 96 h (data not shown). The subtractive hybridization and differential display analyses of HMBA-induced at 96 h and non-induced MEL cells identified 63 differentially expressed genes. Since we were primarily interested in the regulation of normal and malignant hematopoietic differentiation we focused on four genes known to be associated with chromatin remodeling. Figure 1 shows Northern blot analysis of the selected genes functionally involved in chromatin remodeling. High mobility group-17 (HMG-17) was expressed in HMBA-induced MEL cells while almost undetectable in the non-induced controls. Transcripts of high mobility group-1 (HMG-1), topoisomerase II (TOP2), and SMARCA5 were expressed in non-induced MEL cells while in HMBA-induced MEL cells they were mostly undetectable. These data thus strongly suggest the involvement of the chromatin remodeling factors in erythroid differentiation in vitro.
SMARCA5 expression is turned on in CD34
+ AML cell population
The expression of HMG-17, HMG-1, TOP2 and SMARCA5 in CD34 + progenitors of AML patients was assessed by Leukemia semiquantitative RT-PCR. The expression of the first three genes did not show any significant variations as compared to normal CD34 + cells (data not shown). On the other hand, SMARCA5 mRNA was abundantly expressed in leukemic CD34 + cells while it was not detected whatsoever in normal CD34 + controls (Figure 2a ). SMARCA5 mRNA levels in CD34 + progenitors were monitored both at the time of diagnosis and after the achievement of complete hematologic remission. SMARCA5 mRNA expression was decreased in CD34 + cells in the state of complete remission as compared to SMARCA5 level prior to the treatment (Figure 2b) . Remission-associated differentiation of CD34
+ cell population was confirmed by increased mRNA levels of ␤-globin. We also determined the in vitro behavior of hematopoietic progenitors from the AML patients in a standard semisolid agar culture assay. Before the treatment the growth of CFU-GM colonies was low or at zero levels whereas leukemic clusters were observed. After the achievement of the complete hematologic remission CFU-GM colonies formed normally (data not shown).
SMARCA5 is down-regulated in phenylhydrazineinduced accelerated erythropoiesis in vivo
Murine model of experimental anemia induced by phenylhydrazine was used to evaluate the physiological role of SMARCA5 during in vivo accelerated red cell recovery. In the mice treated with phenylhydrazine a rapid drop of hematocrit was followed by an increased serum EPO level with the subsequent recovery of erythrocytes (Figure 3a) . We analyzed the expression of SMARCA5, HMG-17, TOP2, and HMG-1 in the spleen before and during the acceleration of erythropoiesis by Northern blotting. At 5 h post-phenylhydrazine treatment, we observed the increased expression of ␤-globin mRNA, while at the time points of 10, 24, 48, 96 and 120 h its expression was comparable to that in control spleens (data not shown). HMG-17 mRNA expression increased in a similar fashion as ␤-globin. SMARCA5, TOP2, and HMG-1 were almost completely down-regulated at 5 h suggesting their expression was silenced during erythroid acceleration (Figure 3b) . Total bone marrow of phenylhydrazine-treated mice was also analyzed at the same time-points by semiquantitative RT-PCR. ␤-globin expression levels increased within 48 to 96 h after phenylhydrazine administration. HMG-17 expression consistently preceded the rising expression of ␤-globin. Interestingly, SMARCA5 was almost completely down-regulated when erythrocyte counts dropped and serum EPO increased (Figure 3c ). SMARCA5 was highly expressed in the untreated mouse bone marrow and spleen. The expression of SMARCA5 in non-hematopoietic tissues: heart, liver, and kidney exhibited significantly lower expression as detected by Northern blotting (data not shown). As the nature of SMARCA5 expression follows a similar pattern during both in vivo and in vitro erythroid differentiation, we propose that this gene may be critically involved in the regulatory mechanisms of hematopoietic differentiation.
Discussion
Our strategy of identification of the leukemia-associated regulatory factors was based upon the presumption that these genes are involved in hematopoietic differentiation. We identified a subset of chromatin remodeling genes differentially expressed during erythroid differentiation of murine erythroleukemia cell line, a well characterized model of hematopoietic differentiation 13 and determined their expression pattern in normal and malignant hematopoietic cells.
The genes we have studied are involved in chromatin remodeling, however they function by different mechanisms. HMG-17 binds to a nucleosome and modifies the nucleosomal organization to unfold the higher order chromatin structure and thus facilitates the access to the underlying DNA sequence.
14 Therefore, only a small fraction of the nucleosomes contain HMG-17 in vivo, suggesting it is clustered to allow transcription of certain domains.
14 HMG-17 expression decreased in chicken erythroid cells during embryogenesis and also during chicken erythrocyte maturation. 15 It was down-regulated during differentiation of the myeloid HL-60 cell line. 16 This suggests HMG-17 expression to be downregulated in erythroid cells during terminal erythroid maturation and in non-erythroid cells induced to differentiation. We show that HMG-17 is over-expressed when early erythroid progenitor cells begin to differentiate and that it follows the expression pattern of ␤-globin in vitro and in vivo during hematopoietic differentiation.
Similarly to HMG-17, HMG-1 is a nuclear protein involved in regulation of transcription by interacting transiently with nucleosomes during dynamic processes of chromatin remodeling. 17 Its yeast homologue ABF2 co-operates with a DNA topoisomerase and binds approximately 5-10 times more tightly to negatively supercoiled DNA than to relaxed circular or linear DNA. 18 HMG-1 expression does not change during the cell cycle, and it is dramatically down-regulated when muscle cells begin to differentiate. 19 We showed that HMG-1 is down-regulated when hematopoietic cells undergo erythroid differentiation in vitro as well as in vivo. However, neither HMG-17, nor HMG-1 mRNA expression differed in AML CD34
+ progenitors from normal CD34 + cells, which suggest these genes are not differentially regulated in acute leukemia.
Imitation switch gene, Drosophila homologue of SMARCA5, 20 and TOP2 are members of a chromatin-accessibility complex (CHRAC) which uses energy to increase the general accessibility of DNA in chromatin. 12 Imitation switch Leukemia gene is a member of two other chromatin remodeling complexes: NURF (nucleosome remodeling factor) and ACF (ATPdependent chromatin assembly and remodeling factor). 6 Our data on MEL cells showed SMARCA5 and TOP2 were downregulated when the hematopoietic cells were induced to differentiate. We then isolated AML and normal early hematopoietic CD34
+ progenitors to determine mRNA expression of SMARCA5 in these cells. We detected increased mRNA expression of SMARCA5 but not TOP2 in AML CD34
+ cells compared to normal bone marrow CD34 + progenitors, suggesting SMARCA5 is differentially regulated in leukemic progenitors. The role of SMARCA5 has already been implicated in accelerated cell proliferation and viability. 6, 21 The fact that AML progenitors have increased expression of SMARCA5, and this expression decreases in CD34
+ progenitors after achieving a complete remission, may suggest either leukemia hematopoietic progenitors over-expressed SMARCA5 or its expression in normally differentiating leukemia progenitors is down-regulated. It would imply SMARCA5 to be involved in chromatin remodeling which does not allow the normal differentiation of malignant cells. This contention is also supported by the studies suggesting that ATP-dependent remodeling of a nucleosome is an early step in the regulatory process, and that it precedes the binding of most transcription factors to DNA. Furthermore, in most cases the remodeled state can revert back, albeit slowly, to a standard nucleosomal state in the absence of switch gene (SW1/SNF) action. 22 Since SMARCA5 was not studied in normal murine hematopoietic differentiation, we also determined its expression pattern in mice. We found increased SMARCA5 expression in murine hematopoietic tissues, bone marrow and spleen, compared to kidney, liver, and heart. To study SMARCA5 expression kinetics during a physiologic red cell recovery, we also used a murine model of accelerated erythropoiesis, in which hematocrit drop after hemolysis is followed by increased serum EPO levels, formation of erythroid spleen, and subsequent normalization of hematocrit. In both hematopoietic organs: bone marrow and spleen, SMARCA5 expression decreased with erythropoiesis acceleration. This suggests that SMARCA5 expression was down-regulated shortly after induction of differentiation in vivo.
We showed SMARCA5 is expressed in hematopoietic tissues in mice and its expression is down-regulated during in vivo and in vitro erythroid differentiation. TOP2 and HMG-1 gave similar results while HMG-17 was up-regulated during in vivo and in vitro erythroid differentiation. Moreover, SMARCA5 may play a critical regulatory role in malignant hematopoiesis in leukemia since early hematopoietic progenitors of AML over-express SMARCA5. Isolation of the murine full length SMARCA5 cDNA will help to study the effect of induced SMARCA5 expression at the level of embryonic stem cell differentiation, which is required for delineation of its specific role in normal and malignant hematopoiesis. zimkova, B Krasna, D Singerova, and D Dyrova for outstanding technical assistance, and to the clinical, cytogenetic, and tissue culture departments at the Institute of Hematology and Blood Transfusion in Prague for allowing us to use their databases.
